CClinicalTrials.gg
Sign In
Not yet recruitingNCT06901180Updated Mar 28, 2025

in Our Study we Compare Results of Two Oncoplastic Breast Surgery (Short Scar Reduction Mammoplasty and Wise Pattern Reduction Mammoplasty) as Surgical Treatment of Breast Cancer

An observational study in Evaluation of Short Scar Periareolar Inferior Pedicle Reduction Mammoplasty in Oncoplastic Breast Surgery, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
25 Years to 75 Years
Sex
Female
01

Study summary

in our study we compare results of two oncoplastic breast surgery (short scar reduction mammoplasty and wise pattern reduction mammoplasty) as surgical treatment of breast cancer

02

Conditions studied

  • Evaluation of Short Scar Periareolar Inferior Pedicle Reduction Mammoplasty in Oncoplastic Breast Surgery
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

female patients aged from 25 years to 75 years with early breast cancer that meet inclusion and exclusion criteria

Inclusion criteria

  1. Female patients with ages ranging from 25 to 75 years.
  2. Patients with operable breast cancer (Stage I, II and IIIa).
  3. Patients with moderate to large /ptotic breasts.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a contraindication to breast conservative surgery:

    1. Multi-centric disease that can't be incorporated by local excision through a single incision that achieves adequate safety margin and satisfactory cosmetic results.
    2. inflammatory carcinoma.
    3. Contraindications to postoperative radiation e.g. pregnancy, pre-existing lung disease with reduced diffusing capacity and pulmonary TB.
    4. diffuse suspicious malignant micro-calcification on mammography.
    5. inability to attain negative surgical margins.
    6. cardiomyopathy
    7. connective tissue disorders with significant vasculitis.
  2. Previous chest wall or breast radiation.
  3. Patients' refusal participation.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • short scar periareolar inferior pedicle reduction mammoplasty

    oncoplastic reduction mammoplasty through peri-areolar incision

    Procedure: short scar periareolar inferior pedicle reduction mammoplasty

  • wise pattern reduction mammoplasty

    reduction mammoplasty through inverted T incision

Interventions

  • Procedureshort scar periareolar inferior pedicle reduction mammoplasty

    reduction mammoplasty that minimizes scar with better cosmetic outcomes

06

What researchers measure

Primary outcomes

  1. oncological outcomes

    detect incidence of local recurrence of malignancy

    Time frame: 1 year

  2. post operative complications

    surgical complications

    Time frame: 1 month

  3. cosmetic outcomes

    patients' satisfaction with their breast

    Time frame: 1 year

07

Study locations

1 site
  • Sohag University
    Sohag, 82524, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06901180
Lead sponsor
Sohag University
Responsible party
Ahmed Gadelkarim Mohamed (asistant lecturer, Sohag University) — Principal investigator
First posted
Mar 28, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Mar 28, 2025

Study contacts

ahmed gadelkarim, ms
Contact
ahmedgadalkreem@gmail.com
01121280177 ext. 02

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University

Start the discussion